TRK-001 + everolimus

TRK-001 + everolimus is an experimental combination therapy comprising TRK-001 (no publicly available evidence for a drug or molecule named "TRK-001"; the most similar are ONC201/TIC10 or TRK inhibitors, but "TRK-001" specifically is not found in the literature) and everolimus, an oral small molecule inhibitor of mechanistic target of rapamycin (mTOR). Everolimus inhibits the mTOR pathway, a central regulator of cell growth, proliferation, and survival in cancer cells, and is approved for multiple indications including advanced renal cell carcinoma. Preclinical and clinical studies have demonstrated that combining mTOR inhibitors such as everolimus with other targeted agents can enhance antitumor effects and overcome resistance mechanisms in various cancers. This combination is under investigation for its synergistic ability to inhibit tumor growth, particularly in cancers resistant to standard mTOR-targeted therapies.

Other names

RAD001RAD-001RAD 001